Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
The recent publication of a national guideline and quality standards in Canada have provided clinicians with new, evidence-based recommendations on safe, appropriate opioid use.
This study aimed to determine the feasibility and safety of a tapering dose of lisdexamfetamine for the treatment of acute methamphetamine (MA) withdrawal.
We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.
The therapeutic benefits of cannabinoids remain unclear, especially when weighted against their adverse effects.
This review of clinical research reports the evidence regarding biomedical and behavioral treatments for psychostimulant withdrawal symptoms.
To understand what prescribing characteristics are associated with opioid overdose following buprenorphine taper.
Some Rights Reserved National Safer Supply Community of Practice
